164
Views
0
CrossRef citations to date
0
Altmetric
Research Paper

Effects of LATISSE (bimatoprost 0.03 per cent topical solution) on the ocular surface

, OD MSc FAAO FBCLA, , OD FAAO, , OD, , PhD, , MD & , PhD FAAO CLVT
Pages 583-589 | Received 27 Jul 2016, Accepted 13 Oct 2016, Published online: 15 Apr 2021
 

Abstract

Purpose

LATISSE is marketed for the treatment of hypotrichosis (loss of eyelashes), using a prostamide analogue and preserved with benzalkonium chloride, which is an effective preservative; however, it also causes irritation to the ocular surface. LATISSE is applied to the lid margin; however, with the blink, some solution may fall onto the ocular surface. The objective of this study was to assess the effects of LATISSE on the ocular surface over two months.

Methods

Non‐dry eye participants interested in eyelash lengthening were invited to a prospective uncontrolled, open‐label clinical study using LATISSE for two months. Eyelash length, subjective symptoms, tear film stability, osmolarity, ocular redness and intraocular pressure were evaluated at baseline (T0) and at one (T1) and two months (T2).

Results

Twenty‐eight women (ages 18 to 29) entered the study. Fifteen completed the study with five who discontinued due to burning upon instillation and eight were lost to follow‐up. Average eyelash length increased at each time (p < 0.001). Dryness, burning and grittiness remained low (less than 25/100) throughout the trial with dryness showing a significant change between T0 and T1 (p = 0.04), but not between T1 and T2 (p > 0.05). No difference (p > 0.05) was noted for the non‐invasive break‐up time, photochromametry or tear osmolarity. Intraocular pressure showed a decrease with time but translated to only a one to two mmHg change, which was not clinically relevant.

Conclusions

LATISSE increases eyelash length within a short time (less than two months). Patients seeking eyelash enhancement options should be educated as to the use, precautions and any secondary effects, including the potential for discomfort upon instillation.

ACKNOWLEDGEMENTS

Allergan Canada and the Canadian Optometric Education Trust Fund (COETF) funded this project. WW is supported by a FRQS junior career grant #28881. We thank Micheline Gloin for assistance with graphics.

Additional information

Funding

Canadian Optometric Education Trust Fund
FRQS junior career grant

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.